Sævik Marte, Andersen Marit Helen, Beitnes Jan Otto, Aaberge Lars, Halvorsen Per Steinar
The Intervention Centre, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Faculty of Medicine, University of Oslo, Oslo, Norway.
J Patient Rep Outcomes. 2025 May 26;9(1):58. doi: 10.1186/s41687-025-00894-1.
The study aimed to determine the proportion of patients with significant improvements in Health-Related Quality of Life (HRQoL) 12 months after Transcatheter Aortic Valve Implantation (TAVI), using a threshold for physical function (PF) and physical role (RP) domains of the SF-36 questionnaire. Additionally, we explored shared baseline characteristics of patients reporting these improvements.
In this prospective observational study, 88 patients with symptomatic, severe aortic stenosis (AS) and preserved ejection fraction were enrolled between April 2017 and February 2020. Exclusion criteria were clinical instability, pacemaker, chronic AF, comorbidities with life expectancy < 1 year. HRQoL was evaluated before and 12 months after transfemoral TAVI using the Norwegian version 2.0 of SF-36, and presented as mean (95% confidence interval). Other outcome measures were 6-minute walking test and NYHA- classification. Independent samples t-test or Mann-Whitney U test was used for between-group comparisons as appropriate. Logistic regression or Chi2-test were used to explore associations between changes in PF and RP and clinical parameters. Statistical significance was set at p ≤ 0.05, and clinically significant changes in HRQoL were defined as increase of ≥ 15 points in the PF and RP categories.
Mean age of the cohort was 80 ± 6 years. 44 (50%) patients reported clinically significant improvement in PF, and 46 (52%) in the RP domain. Baseline scores were significantly lower in patients reporting clinical improvement after TAVI, with PF scores pre intervention 43.07 (37.37-48.78) vs. 65.34 (59.01-71.68), p < 0.001, and RP 36.01 (29.56-42.46) vs. 59.92 (50.91-68.92), p < 0.001. No significant associations were found between improvement in domain scores and parameters from the routine baseline examination, but having ≥ 15-point improvement correlated to baseline PF and RP scores.
Our study highlights the importance of defining a uniform threshold for clinically significant improvement in the SF-36 HRQoL questionnaire for patients undergoing TAVI. Half of the patients reported favorable long-term outcome for PF and RP aspects of SF-36. This emphasizes the importance of HRQoL assessment in the preoperative work up for patients undergoing TAVI.
gov/ 05.04.2017 with ID NCT03107923.
本研究旨在通过使用SF-36问卷中身体功能(PF)和身体角色(RP)领域的阈值,确定经导管主动脉瓣植入术(TAVI)12个月后健康相关生活质量(HRQoL)有显著改善的患者比例。此外,我们还探究了报告这些改善的患者的共同基线特征。
在这项前瞻性观察性研究中,2017年4月至2020年2月期间纳入了88例有症状的严重主动脉瓣狭窄(AS)且射血分数保留的患者。排除标准为临床不稳定、起搏器、慢性房颤、预期寿命<1年的合并症。使用SF-36挪威语2.0版本在经股动脉TAVI术前和术后12个月评估HRQoL,并以均值(95%置信区间)表示。其他结局指标为6分钟步行试验和纽约心脏协会(NYHA)分级。根据情况使用独立样本t检验或曼-惠特尼U检验进行组间比较。使用逻辑回归或卡方检验探究PF和RP变化与临床参数之间的关联。统计学显著性设定为p≤0.05,HRQoL的临床显著变化定义为PF和RP类别增加≥15分。
该队列的平均年龄为80±6岁。44例(50%)患者报告PF有临床显著改善,46例(52%)患者报告RP领域有临床显著改善。TAVI术后报告临床改善的患者基线评分显著更低,干预前PF评分为43.07(37.37 - 48.78),而改善后为65.34(59.01 - 71.68),p<0.001;RP干预前为36.01(29.